Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New pituitary oncogenes.

A P Heaney1, S Melmed

  • 1Department of Medicine, Cedars-Sinai Research Institute, UCLA School of Medicine, Los Angeles, California 90048, USA.

Endocrine-Related Cancer
|May 16, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consensus and controversies about diagnosing GH deficiency: a Delphi survey by the GH research society.

Pituitary·2025
Same author

Medical management pathways for Cushing's disease in pituitary tumors centers of excellence (PTCOEs).

Pituitary·2025
Same author

Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE).

Pituitary·2024
Same author

Pilot study to define criteria for Pituitary Tumors Centers of Excellence (PTCOE): results of an audit of leading international centers.

Pituitary·2023
Same author

Expression of leukemia inhibitory factor in craniopharyngioma.

Endocrine pathology·2016
Same author

Sagit©: A Novel Clinician-Reported Outcome for Managing Acromegaly in Clinical Practice.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same journal

The Role of the B7 Family in Autoimmune Thyroid Diseases and Thyroid Cancer.

Endocrine-related cancer·2026
Same journal

Lineage-Specific Steroidomic Signatures in Pituitary Neuroendocrine Tumors: Pregnenolone Enrichment in SF-1 Lineage and Associations with Tumor Behavior.

Endocrine-related cancer·2026
Same journal

Characterization of SF3B1 role in prolactin-secreting pituitary tumors.

Endocrine-related cancer·2026
Same journal

The NET Score: An Interpretable AI-Assisted Prognostic Score for Mortality Risk in Lung Neuroendocrine Tumors.

Endocrine-related cancer·2026
Same journal

Intraprostatic steroid hormones and endocrine disruptors in prostate cancer.

Endocrine-related cancer·2026
Same journal

Functional Imaging in Hereditary Endocrine Neoplasms: Evolving Modalities and Clinical Implications.

Endocrine-related cancer·2026
See all related articles

Pituitary tumors arise from genetic mutations and hormonal influences, driving tumor growth. Understanding these molecular mechanisms offers new pathways for early detection and targeted therapies for pituitary neoplasms.

Area of Science:

  • Endocrinology
  • Oncology
  • Molecular Biology

Background:

  • Pituitary tumors are common monoclonal neoplasms associated with significant morbidity and mortality.
  • Despite recent advances, no definitive tumor marker aids clinical or therapeutic decisions for pituitary tumors.
  • The molecular events in pituitary tumorigenesis are complex, involving genetic mutations and hormonal signaling.

Purpose of the Study:

  • To review recent developments in understanding the molecular mechanisms of pituitary tumor pathogenesis.
  • To highlight the potential of molecular insights for improved pituitary tumor management.
  • To discuss the role of molecular probes in predicting tumor behavior and guiding therapy.

Main Methods:

  • This is a review article, synthesizing current knowledge on pituitary tumor molecular pathogenesis.

Related Experiment Videos

  • It examines the interplay of genetic mutations (activating and inactivating) and hormonal factors.
  • The review discusses the cooperative roles of hypothalamic hormones, circulating hormones, growth factors, and cytokines.

    • Main Results:

    • Activating and inactivating mutations, alongside hormonal and growth factor signaling, drive pituitary tumor expansion.
    • Understanding these molecular pathways is crucial for comprehending pituitary tumorigenesis.
    • No single tumor marker has yet emerged to guide clinical and therapeutic decisions.

    Conclusions:

    • New molecular insights into pituitary tumor pathogenesis are emerging.
    • Molecular probes hold promise for early prediction of tumor behavior.
    • Targeted therapies and novel management strategies for pituitary tumors can be developed based on these molecular findings.